Reading the adjunct evidence the way a reviewer would The pivotal liraglutide trials, ADJUNCT ONE and TWO, showed HbA1c effects below the regulatory threshold alongside dose-related ketosis and symptomatic hypoglycaemia, and the FDA did not approve liraglutide for type 1 on efficacy and safety grounds.6 The newer story is the automated-insulin-delivery era: ADJUST-T1D paired weekly semaglutide with an AID system in 72 adults with type 1 and obesity, and a composite goal (time in range above 70%, time below range under 4%, and at least 5% weight loss) was met by 36% versus 0% on placebo, with no ketoacidosis.8 Tirzepatide in type 1 rests on a single-centre observational cohort of 26 with no control arm
By crossing the blood-brain barrier, supplying the Acetyl-CoA necessary for acetylcholine synthesis, and repairing the mitochondrial machinery that produces ATP, ALCAR provides the brain and body with the essential tools needed to begin restoring metabolic balance
If you are cutting what kind of deficit are we looking at
Improved insulin sensitivity: A 2022 trial found 500 mg daily for 6 months lowered HbA1c in elderly diabetics
10.1016/j.imlet.2018.03.008 88